STOCK TITAN

IMMUNIC (IMUX) director granted 25,370 stock options at $14.80 strike

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

IMMUNIC, INC. director Simona Skerjanec received a grant of stock options covering 25,370 shares of common stock. The options have an exercise price of $14.80 per share and expire on July 5, 2036. They vest in monthly increments over one year from the grant date, and following this grant she holds 25,370 options directly.

Positive

  • None.

Negative

  • None.
Insider Skerjanec Simona
Role null
Type Security Shares Price Value
Grant/Award Stock Option 25,370 $0.00 --
Holdings After Transaction: Stock Option — 25,370 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Options granted 25,370 options Stock option award to director on July 5, 2026
Exercise price $14.80 per share Strike price for IMMUNIC common stock underlying options
Underlying shares 25,370 shares IMMUNIC common stock underlying the stock options
Expiration date July 5, 2036 Final expiration of granted stock options
Post-transaction options held 25,370 options Derivative securities beneficially owned following transaction
Vesting schedule Monthly over one year Options vest in monthly increments from grant date
Stock Option financial
"security_title: "Stock Option""
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
exercise price financial
"conversion_or_exercise_price: "14.8000""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Common Stock financial
"underlying_security_title: "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
expiration date financial
"expiration_date: "2036-07-05T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vests in monthly increments financial
"The option vests in monthly increments over a period of one year"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did IMMUNIC (IMUX) report for Simona Skerjanec?

IMMUNIC reported that director Simona Skerjanec received a grant of stock options for 25,370 shares of common stock. The options were awarded at an exercise price of $14.80 per share and represent a compensation-related acquisition, not an open-market purchase or sale.

What are the key terms of Simona Skerjanec’s IMMUNIC (IMUX) stock options?

The granted stock options cover 25,370 shares of IMMUNIC common stock at an exercise price of $14.80 per share. They expire on July 5, 2036 and vest in monthly increments over one year from the grant date, aligning with typical director compensation practices.

How many IMMUNIC (IMUX) options does Simona Skerjanec hold after this Form 4?

After this grant, Simona Skerjanec holds 25,370 IMMUNIC stock options directly. This entire position comes from the reported award, as the Form 4 shows 25,370 derivative securities beneficially owned following the transaction, with no additional derivative holdings listed.

Is the IMMUNIC (IMUX) Form 4 transaction an insider buy or a compensation grant?

The Form 4 reflects a compensation grant, not an open-market insider buy. The transaction is coded as an award (Code A), described as a grant, award, or other acquisition, with no cash price paid and a fixed $14.80 exercise price for future potential share acquisition.

When do Simona Skerjanec’s IMMUNIC (IMUX) options vest and expire?

The options vest in monthly increments over one year from the grant date, spreading vesting across twelve months. They carry a long-term expiration date of July 5, 2036, giving a multi-year window during which vested options can potentially be exercised at $14.80 per share.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Skerjanec Simona

(Last)(First)(Middle)
1200 AVENUE OF THE AMERICAS, SUITE 200

(Street)
NEW YORK NEW YORK 10036

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
IMMUNIC, INC. [ IMUX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/05/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option$14.807/05/2026A25,370 (1)07/05/2036Common Stock25,370$0.0025,370D
Explanation of Responses:
1. The option vests in monthly increments over a period of one year from the grant date.
/s/ Simona Skerjanec07/07/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)